scholarly journals In vitro and in vivo Protection against Indomethacin-Induced Small Intestinal Injury by Proton Pump Inhibitors, Acid Pump Antagonists, or Indomethacin-Phosphatidylcholine

Digestion ◽  
2012 ◽  
Vol 86 (2) ◽  
pp. 171-177 ◽  
Author(s):  
Yun Jeong Lim ◽  
Tri M. Phan ◽  
Elizabeth J. Dial ◽  
David Y. Graham ◽  
Lenard M. Lichtenberger
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Intestinal Injury ◽  
Small Intestinal Injury ◽  
Small Intestinal

Tu1239 Prophylactic Effects of Proton Pump Inhibitors on NSAIDs Induced Small Intestinal Injury in Rats

2014 ◽  
Vol 146 (5) ◽  
pp. S-792
Author(s):  
Satoshi Harada ◽  
Eiji Umegaki ◽  
Shoko Edogawa ◽  
Ken Narabayashi ◽  
Kaori Fujiwara ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Intestinal Injury ◽  
Small Intestinal Injury ◽  
Small Intestinal

Proton Pump Inhibitors Exacerbate NSAID-Induced Small Intestinal Injury by Inducing Dysbiosis

2011 ◽  
Vol 141 (4) ◽  
pp. 1314-1322.e5 ◽  
Author(s):  
John L. Wallace ◽  
Stephanie Syer ◽  
Emmanuel Denou ◽  
Giada de Palma ◽  
Linda Vong ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Intestinal Injury ◽  
Small Intestinal Injury ◽  
Small Intestinal

Proton Pump Inhibitors and Low-Dose Aspirin Markedly Exacerbate NSAID-Induced Small Intestinal Injury: A Link to Dysbiosis?

2011 ◽  
Vol 140 (5) ◽  
pp. S-87 ◽  
Author(s):  
John L. Wallace ◽  
Emmanuel Denou ◽  
Linda Vong ◽  
Stephanie D. Syer ◽  
Webb McKnight ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Low Dose ◽  
Intestinal Injury ◽  
Dose Aspirin ◽  
Low Dose Aspirin ◽  
Small Intestinal Injury ◽  
Small Intestinal

scholarly journals The impact of proton pump inhibitors on the pharmacokinetics of voriconazole in vitro and in vivo

2018 ◽  
Vol 108 ◽  
pp. 60-64 ◽  
Author(s):  
Miao Yan ◽  
Zhu-feng Wu ◽  
Dan Tang ◽  
Feng Wang ◽  
Yi-wen Xiao ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
The Impact

Proton pump inhibitors as a possible cause of vitiligo: an in vivo and in vitro study

2013 ◽  
Vol 28 (11) ◽  
pp. 1475-1479 ◽  
Author(s):  
J.M. Shin ◽  
J.Y. Lee ◽  
D.Y. Lee ◽  
T.Y. Yoon ◽  
J.C. Lee ◽  
...  
Keyword(s):  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
In Vitro Study ◽  
Vitro Study ◽  
Possible Cause

The deleterious association between proton pump inhibitors and prostate cancer specific death.

2020 ◽  
Vol 38 (6_suppl) ◽  
pp. 309-309
Author(s):  
Hanan Goldberg ◽  
Faizan Moshin ◽  
Refik Saskin ◽  
Girish S. Kulkarni ◽  
Alejandro Berlin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Cox Regression ◽  
Population Based ◽  
Study Data ◽  
History Of ◽  
Time Dependent Covariates

309 Background: Proton pump inhibitors (PPIs) are a commonly prescribed class of medications. Although in-vitro and in-vivo data have shown PPIs to have anti-tumor effects, more recent studies suggest an increased cancer risk in several solid organs. Pantoprazole, a commonly prescribed PPI, has been shown to harbor a protective effect in human prostate cancer (PCa) cells. We aimed to investigate the effect of pantoprazole and other PPIs on PCa-specific death and additional PCa outcomes. Methods: In this retrospective, population-based cohort study, data were incorporated from the Institute for Clinical and Evaluative Sciences to identify all men aged 66 and above with a history of a single negative prostate biopsy between 1994 and 2016. We used multivariable Cox regression models with time-dependent covariates, to assess the effect of PPIs on PCa diagnosis, androgen deprivation therapy (ADT) use, and PCa-specific death. All models included other medications with a putative effect on PCa. All models were adjusted for age, rurality, comorbidity, and year of patient study inclusion. Results: Overall, 21,512 men were included, with a mean follow-up time of 8.06 years (SD 5.44 years). A total of 10,999 patients (51.1%) used a PPI. A total of 5,187 patients (24.1%) were diagnosed with PCa, 2,043 patients (9.5%) were treated with ADT, and 805 patients (3.7%) died from PCa. Pantoprazole was associated with a 3.0% (95% CI 0.3%-6,0%) increased rate of being treated with ADT for every six months of cumulative use, while any use of all other PPIs was associated with a 39.0% (95% CI 18.0%-64.0%) increased PCa-specific mortality. No significant association was found with PCa diagnosis. Conclusions: Upon validation of the potentially negative association of PPIs with PCa outcomes, the expansive use of PPIs may need to be reassessed, especially in PCa patients.

In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors

2015 ◽  
Vol 29 (6) ◽  
pp. 604-614 ◽  
Author(s):  
Edouard Ollier ◽  
Sophie Hodin ◽  
Thierry Basset ◽  
Sandrine Accassat ◽  
Laurent Bertoletti ◽  
...  
Keyword(s):  
Drug Interaction ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
In Vivo Evaluation ◽  
Drug Drug Interaction

Dietary protein digestion and absorption are impaired during acute postexercise recovery in young men

2013 ◽  
Vol 304 (5) ◽  
pp. R356-R361 ◽  
Author(s):  
Kim van Wijck ◽  
Bart Pennings ◽  
Annemarie A. van Bijnen ◽  
Joan M. G. Senden ◽  
Wim A. Buurman ◽  
...  
Keyword(s):  
Dietary Protein ◽  
Young Men ◽  
Intestinal Injury ◽  
Protein Digestion ◽  
Absorption Kinetics ◽  
Small Intestinal Injury ◽  
Small Intestinal ◽  
Postexercise Recovery ◽  
The Impact

Previously, we demonstrated that exercise can cause small intestinal injury, leading to loss of gut barrier function. The functional consequences of such exercise-induced intestinal injury on subsequent food digestion and absorption are unclear. The present study determined the impact of resistance-type exercise on small intestinal integrity and in vivo dietary protein digestion and absorption kinetics. Twenty-four young males ingested 20 g specifically produced intrinsically l-[1-13C]phenylalanine-labeled protein at rest or after performing a single bout of resistance-type exercise. Continuous intravenous infusions with l-[ring-2H5]phenylalanine were employed, and blood samples were collected regularly to assess in vivo protein digestion and absorption kinetics and to quantify plasma levels of intestinal fatty-acid binding protein (I-FABP) as a measure of small intestinal injury. Plasma I-FABP levels were increased after exercise by 35%, reaching peak values of 344 ± 53 pg/ml compared with baseline 254 ± 31 pg/ml ( P < 0.05). In resting conditions, I-FABP levels remained unchanged. Dietary protein digestion and absorption rates were reduced during postexercise recovery when compared with resting conditions ( P < 0.001), with average peak exogenous phenylalanine appearance rates of 0.18 ± 0.04 vs. 0.23 ± 0.03 mmol phenylalanine·kg lean body mass−1·min−1, respectively. Plasma I-FABP levels correlated with in vivo rates of dietary protein digestion and absorption ( r S = −0.57, P < 0.01). Resistance-type exercise induces small intestinal injury in healthy, young men, causing impairments in dietary protein digestion and absorption kinetics during the acute postexercise recovery phase. To the best of our knowledge, this is first evidence that shows that exercise attenuates dietary protein digestion and absorption kinetics during acute postexercise recovery.

Sign in / Sign up

Export Citation Format

Share Document